

**eLife Sciences Publications, Ltd**

Financial Statements

December 31, 2020 and 2019

(With Independent Auditor's Report Thereon)

**eLife Sciences Publications, Ltd**

Financial Statements

December 31, 2020 and 2019

**Table of Contents**

	<b>Page</b>
Independent Auditor's Report	1 – 2
Balance Sheet	3
Statements of Activities	4
Statements of Functional Expenses	5
Statements of Cash Flows	6
Notes to Financial Statement	7 – 14

## **Independent Auditor's Report**

The Board of Directors  
eLife Sciences Publications, Ltd:

### **Report on the Financial Statements**

We have audited the accompanying financial statements of eLife Sciences Publications, Ltd, which comprise the balance sheets as of December 31, 2020 and 2019, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

### **Management's Responsibility for the Financial Statements**

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### **Auditor's Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

## Independent Auditor's Report (continued)

### Opinion

In our opinion, the financial statements referred to above present fairly in all material respects, the financial position of eLife Sciences Publications Ltd as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

A handwritten signature in black ink that reads "Grant Thornton UK LLP". The signature is written in a cursive, flowing style. A long, thin horizontal line is drawn across the top of the signature, extending from the left edge of the page towards the right.

Grant Thornton UK LLP

London, United Kingdom

4 June 2021

**eLife Sciences Publications, Ltd**

Balance Sheet

Years ended December 31

	<b>2020</b>	<b>2019</b>
	<b>£000</b>	<b>£000</b>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	<b>1,022</b>	1,317
Trade receivables	<b>163</b>	143
Other receivables and prepayments	<b>270</b>	339
Corporation tax	<b>160</b>	-
Total current assets	<b>1,615</b>	1,799
Non-current assets:		
Other receivables and prepayments	<b>82</b>	82
Property, plant, and equipment:		
Machinery and equipment	<b>187</b>	181
Leasehold improvements	<b>191</b>	191
	<b>378</b>	372
Less accumulated depreciation and amortisation	<b>(234)</b>	(173)
Net property, plant and equipment	<b>144</b>	199
Total non-current assets	<b>226</b>	281
Total assets	<b>1,841</b>	2,080
<b>Liabilities and Net Assets</b>		
Current liabilities:		
Trade accounts payable	<b>102</b>	111
Accrued expenses	<b>430</b>	423
Contract liabilities	<b>112</b>	132
Deferred grant income	<b>714</b>	525
Deferred tax provision	-	17
Other liabilities	<b>80</b>	79
Total current liabilities	<b>1,438</b>	1,287
Net assets:		
Net assets without donor restrictions	<b>403</b>	793
Total net assets	<b>403</b>	793
Total liabilities and net assets	<b>1,841</b>	2,080

See accompanying notes to the financial statements.

**eLife Sciences Publications, Ltd**

Statements of Activities

Years ended December 31

	<b>2020</b>	<b>2019</b>
	<b>£000</b>	<b>£000</b>
<b>Revenue</b>		
Publication fees	<b>3,536</b>	2,655
Contributions	<b>2,034</b>	3,360
Total revenue	<b>5,570</b>	6,015
<b>Expenses</b>		
Program services:		
Journal expenses	<b>5,190</b>	5,083
Supporting services:		
Management and general	<b>787</b>	625
Total services expenses	<b>5,977</b>	5,708
(Loss)/profit before tax	<b>(407)</b>	307
Income tax benefit / (expense)	<b>17</b>	(58)
Change in net assets	<b>(390)</b>	249
Net assets, beginning of year	<b>793</b>	544
Net assets, end of year	<b>403</b>	793

See accompanying notes to the financial statements.

**eLife Sciences Publications, Ltd**  
Statements of Functional Expenses  
Year ended December 31, 2020

	<b>Program services</b>	<b>Supporting services</b>	<b>Total functional expenses</b>
	<b>Journal expenses</b>	<b>Management and general</b>	
	<b>£000</b>	<b>£000</b>	<b>£000</b>
Salaries	2,084	373	2,457
Payroll taxes	254	23	277
Employee benefits	133	11	144
Occupancy	252	23	275
Editorial costs	1,371	-	1,371
Professional fees	18	178	196
Marketing expenses	285	-	285
Development costs	620	-	620
Other expenses	117	174	291
Depreciation and amortisation	56	5	61
<b>Total functional expenses</b>	<b>5,190</b>	<b>787</b>	<b>5,977</b>

Year ended December 31, 2019

	<b>Program services</b>	<b>Supporting services</b>	<b>Total functional expenses</b>
	<b>Journal expenses</b>	<b>Management and general</b>	
	<b>£000</b>	<b>£000</b>	<b>£000</b>
Salaries	2,049	178	2,227
Payroll taxes	230	20	250
Employee benefits	121	14	135
Occupancy	258	23	281
Editorial costs	1,522	-	1,522
Professional fees	4	234	238
Marketing expenses	306	-	306
Development costs	237	-	237
Other expenses	300	151	451
Depreciation and amortisation	56	5	61
<b>Total functional expenses</b>	<b>5,083</b>	<b>625</b>	<b>5,708</b>

See accompanying notes to the financial statements.

**eLife Sciences Publications, Ltd**

Statements of Cash Flows

Years ended December 31

	<b>2020</b>	<b>2019</b>
	<b>£000</b>	<b>£000</b>
Cash flows provided by operating activities:		
Change in net assets	<b>(390)</b>	249
Adjustments to reconcile change in net assets to cash provided by operating activities:		
Depreciation and amortisation	<b>61</b>	61
Changes in operating assets and liabilities		
(Increase) in trade receivables	<b>(20)</b>	(12)
Decrease / (increase) in other receivables and prepayments	<b>69</b>	(13)
(Decrease) in trade accounts payable	<b>(9)</b>	(81)
Increase / (decrease) in accrued expenses	<b>7</b>	(392)
(Decrease) / Increase in contract liabilities	<b>(20)</b>	8
Increase / (decrease) in deferred grant income	<b>189</b>	(316)
(Decrease) / increase in tax liabilities	<b>(177)</b>	(18)
Increase / (decrease) in other liabilities	<b>1</b>	(4)
Net cash (used in) operating activities	<b>(289)</b>	(518)
Cash flows from investing activities:		
Purchases of fixed assets	<b>(6)</b>	(25)
Net cash (used in) investing activities	<b>(6)</b>	(25)
Net (decrease) in cash and cash equivalents	<b>(295)</b>	(543)
Cash and cash equivalents, beginning of year	<b>1,317</b>	1,860
Cash and cash equivalents, end of year	<b>1,022</b>	1,317

See accompanying notes to the financial statements.



**eLife Sciences Publications, Ltd**

Notes to Financial Statements

December 31, 2020 and 2019

**1 Summary of Significant Accounting Policies**

**(a) Description of Business**

eLife Sciences Publications, Ltd (the “Company”) was incorporated on 6 October 2011 as a limited liability non-profit non-stock corporation in the State of Delaware, USA. It is exempt from USA Federal income tax under section 501(c)(3) of the Internal Revenue Code.

The primary purpose of the Company is to operate exclusively for charitable, scientific and educational purposes, including, but not limited to, the operation of an open access journal for scientific research, as well as such other activities as required to support the mission of such journal.

**(b) Basis of preparation**

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).

Net assets, revenues, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, the net assets of the Company and changes therein are classified and reported as follows:

Net assets without donor restrictions – Net assets that are not subject to any donor-imposed stipulations.

Net assets with donor restrictions – Net assets subject to donor-imposed restrictions on their use that may be met either by actions of the Company or the passage of time.

As the Company does not consider that any donor-imposed stipulations exceed those already in place due to the Company’s Bylaws, all net assets, revenue, gains and losses have been classified as relating to net assets without donor restrictions.

**(c) Foreign currency**

The Company accounts for its operations using the Great Britain Pound (“GBP”) as the functional currency, as the primary economic environment in which the Company operates is Great Britain. Transactions in United States dollars (“USD”) are recognized at the rates of exchange prevailing at the dates of the transaction. At the end of each reporting period, monetary assets and liabilities denominated in USD are remeasured at the rates prevailing at that date. Foreign currency differences arising on remeasurement of monetary items are recognized in earnings. During 2020, the Company recorded net foreign exchange rate losses of £71,000 (2019: £49,000).

**(d) Use of Estimates**

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial

**eLife Sciences Publications, Ltd**

Notes to Financial Statements

December 31, 2020 and 2019

statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of fixed assets and the valuation of fixed assets.

**(e) Cash and Cash Equivalents**

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

**(f) Trade and Other Receivables**

The Company's trade receivables arise from publication fees to customers and are generally due within 30 days. The Company assesses the status of receivables based on the number of days past due. Management establishes an allowance for doubtful accounts, which is based on a periodic review of the collectability of the receivables in light of historical experience, the nature and volume of the receivables, and other subjective factors. When management determines that a receivable is uncollectible, it is written off against the allowance for doubtful accounts, and payments subsequently received on such receivables are credited to bad debt expense. The Company wrote off no receivables during 2020 and 2019. Management has determined no allowance is required as of December 31, 2020 and 2019.

**(g) Recognition of Publication fee income**

The Company's revenue relates to publication fee revenue that is recorded upon the completion of services for peer review carried out on a manuscript, for the production process, and for the publication of the manuscript on the Company's website.

The Company has a single performance obligation in its publication contracts, which is the publication of the final version of the manuscript on the Company's website. The whole of the contract value is allocated to this single performance obligation.

Publication fees shown in the Statement of Activities is revenue that has been earned in the year on these contracts.

At the year end, trade and other receivables included £163,000 (2019: £143,000) of trade receivables relating to these contracts, plus £58,000 (2019: £34,000) in respect of amounts the Company is entitled to collect from customers but which have not yet been invoiced to customers.

Within contract liabilities is £112,000 (2019: £132,000) representing the value of those invoices in trade receivable (or already paid) where the contract performance obligation had not been satisfied at year end.

The Company does not have any obligations for warranties, returns or refunds.

## **eLife Sciences Publications, Ltd**

Notes to Financial Statements

December 31, 2020 and 2019

### **(h) Recognition of Grant Income**

In accordance with ASC 958-605, the Company records contributions received from funders as increases in net assets without donor restrictions, and presents these contributions as Contributions in the Statement of Activities.

Where contributions relate to funding promises, the contributions are recognised to the extent that any associated conditions are substantially met.

The Company has received conditional funding promises from its Sponsors. These promises are subject to the contributions being drawn down by the Company to meet expected cash requirements consistent with forecasts approved by the Sponsors. These contributions are recognised as income in the period for which the funding has been authorised by the Sponsors. The available unauthorised contributions as at the balance sheet date are £15m (2019: £18m). The maximum draw down in each year is limited, with a limit of not less than £5m.

Since two of the Sponsors, the Howard Hughes Medical Institute and the Wellcome Trust, are also members of the Company their Contributions in the year of £1,287,000 (2019: £2,592,000) are related party transactions. No amounts from related parties were outstanding at 31 December 2020 (2019: £nil).

### **(i) Property, Plant, and Equipment**

Plant, and equipment are stated at cost.

Property, plant and equipment is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method using an estimated useful life of three years and five years for machinery and equipment. Costs related to leasehold improvements are capitalised on properties held under operating leases and depreciated over the lesser of their estimated useful lives or the applicable lease term. Maintenance and repair costs are expensed when incurred and expenditures for major renewals and betterments that extend the useful lives of existing assets are capitalised and depreciated over their respective useful lives. When property, plant or equipment is retired or disposed of, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is reflected in the statements of activities.

Total depreciation for the year ended December 31, 2020 was £61,000 (2019: £61,000).

### **(j) Research and Development and Advertising**

Research and development and advertising costs are expensed as incurred. Research and development costs amounted to £780,000 in 2020 (2019: £584,000). Advertising costs amounted to £44,000 in 2020 (2019: £52,000). These are included within Development costs and Marketing expenses respectively.

### **(k) Functional Allocation of Expenses**

The costs of providing various program and supporting activities have been summarised on a functional basis in the Statements of Functional Expenses. Expenses directly

**eLife Sciences Publications, Ltd**

Notes to Financial Statements

December 31, 2020 and 2019

attributable to a specific functional area of the Company are reported as expenses of those functional areas while indirect cost that benefit multiple functional areas have been allocated amount the various functional areas based on the full time employee equivalent method of allocation.

**(l) Income Taxes**

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. An allowance against deferred tax assets is recorded in whole or in part when it is more likely than not that such tax benefits will not be realized. The Company records interest and penalties to income tax expense in statement of operations.

The Company adopted certain provisions of FASB Accounting Standards Codification ("ASC") Topic 740, "Income Taxes", for the criterion that an individual tax position has to meet for some or all of the benefits of that position to be recognized in the Company's financial statements. All tax positions for which the statute of limitations remains open are subject to evaluation. Only tax positions that meet the more-likely-than-not recognition threshold at the evaluation date will be recognized or continue to be recognized.

Developing the provision for income taxes, including the effective tax rate, and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances management deems necessary to value deferred tax assets. The judgments and tax strategies are subject to audit by various taxing authorities. While management believes they have provided adequately for the income taxes in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial position, results of operations or cash flows. As of the date of the most recent statement of financial position, the Company is subject to examination in the United States of America and United Kingdom for years before 2020.

The Company is exempt from federal income taxes in the United States under Section 501(c)(3) of the Internal Revenue Code of 1986. The Company believes that it has taken no significant uncertain tax positions.

**(m) Retirement Plans**

The Company operates a defined contribution pension plan, and also contributes to the defined contribution pension plans of some of its employees. Contributions payable by the Company are expensed as incurred.

## **eLife Sciences Publications, Ltd**

Notes to Financial Statements

December 31, 2020 and 2019

### **(n) Long-Lived Assets**

Long-lived assets, such as property, plant, and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.

### **(o) Commitments and Contingencies**

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

### **(p) Fair Value Measurements**

The estimated fair value amounts for specific groups of financial instruments are presented within the footnotes applicable to such items. Accounts receivable, accounts payable and accrued expenses are stated at the transaction price, which approximates fair value, due to their short term to maturity. All financial assets are considered to be level 1.

### **(q) Recently Issued Accounting Standards**

In June 2020, the FASB issued ASU No. 2020-05 to update certain provisions of the previously issued ASU No. 2016-02, Leases (ASC 842). The guidance in this ASU supersedes the leasing guidance in Topic 840, Leases. Under the new guidance, lessees are required to recognize lease assets and lease liabilities on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statements of the activities. The new standard is effective for the Company for the year ending December 31, 2022. A modified retrospective approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the effect the provisions of ASU 2016-02 will have on the financial statements.

## **2 Significant Risks and Uncertainties Including Business and Credit Concentrations**

The contributions received by the Company from funders is highly concentrated, and relates to four organisations, which contributed 32%, 32%, 32% and 4% of the contributions in 2020 (2019: four organisations 39%, 39%, 20% and 2%).

**eLife Sciences Publications, Ltd**

Notes to Financial Statements

December 31, 2020 and 2019

**3 Fair Value Measurements and the Fair Value Option**

The carrying amount of the Company's financial instruments, consisting of cash, trade receivable, accounts payable, and accrued liabilities are reasonable estimates of their fair values based on their short-term nature.

**4 Income Taxes**

Reconciliation of income tax expense:

	<b>2020</b>	<b>2019</b>
	<b>£000</b>	<b>£000</b>
(Loss)/profit before tax	<b>(407)</b>	307
Tax on profit before tax at standard corporation tax rate of 19%	<b>(77)</b>	58
Effects of:		
Fixed asset differences	<b>2</b>	2
Expenses not deductible for tax purposes	-	1
R&D expenditure credits	-	(41)
Adjustments to tax charge in respect of previous periods	-	38
Adjust closing deferred tax to average rate of 19%	-	-
Adjust opening deferred tax to average rate of 19%	-	-
Deferred tax not recognised	<b>56</b>	-
Remeasurement of deferred tax for changes in tax rates	<b>2</b>	-
Total income tax (benefit) / expense	<b>(17)</b>	58

Analysis of income tax expense for the period:

	<b>2020</b>	<b>2019</b>
	<b>£000</b>	<b>£000</b>
Current tax		
UK corporation tax at 19%	-	20
Adjustments in respect of prior periods	-	38
Deferred tax		
Origination and reversal of temporary differences	<b>(17)</b>	-
Total income tax expense	<b>(17)</b>	58

The components of deferred tax (assets) and liabilities:

	<b>2020</b>	<b>2019</b>
	<b>£000</b>	<b>£000</b>
Fixed asset temporary differences	<b>(56)</b>	17
Valuation allowance	<b>56</b>	-
Net deferred tax liability	-	17

**eLife Sciences Publications, Ltd**

Notes to Financial Statements

December 31, 2020 and 2019

Movement in provision:

	<b>2020</b> <b>£000</b>	<b>2019</b> <b>£000</b>
Provision at start of period	<b>17</b>	17
Deferred tax charged in income tax expense for the period	<b>(73)</b>	-
Valuation allowance	<b>56</b>	-
Provision at end of period	<b>-</b>	17

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company states those balances at the enacted tax rates expected to be in effect when the taxes are paid or recovered.

**5 Leases**

At December 31, 2020 and 2019 the Company had a noncancelable operating lease, for office property, that expires in 2028, but with a break clause in 2023.

Minimum rent expense under operating leases is recognized on a straight-line basis over the term of the lease including any periods of free rent. Rental expense for operating leases (except those with lease terms of a month or less that were not renewed) during 2020 and 2019 consisted of the following:

	<b>2020</b> <b>£000</b>	<b>2019</b> <b>£000</b>
Minimum rentals	<b>131</b>	129

Future minimum lease payments under noncancelable operating leases as of December 31, 2020 and 2019 are:

Years from balance sheet date:	<b>2020</b> <b>£000</b>	<b>2019</b> <b>£000</b>
1	<b>137</b>	137
2	<b>137</b>	137
3	<b>75</b>	137
4	-	75
5	-	-
	<b>349</b>	486

**eLife Sciences Publications, Ltd**

Notes to Financial Statements

December 31, 2020 and 2019

**6 Retirement plans**

The Company makes contributions into employees' defined contribution pension plans. All employees are eligible to participate. The Company contributes 6% of pay.

Total retirement plan costs for the year ended December 31, 2020 were £143,000 (2019: £134,000).

**7 Commitments and Contingencies**

From time to time, the Company is a party to certain legal proceedings arising in the ordinary course of business. In the opinion of management, there are no current legal proceedings or other claims outstanding which could have a material adverse effect on the results of operations or the financial position of the Company.

**8 Subsequent events**

The Company has evaluated subsequent events from the balance sheet date through 4 June 2021, the date at which the financial statements were available to be issued, and determined that there are no other items to disclose.